Authors
Latest:
New Research to Identify Chemo-Resistant Genes in Ovarian CancerResearch may hasten the effort to determine which strains of cancer will eventually become resistant to chemotherapy, paving the way for developing more effective targeted treatments.
Latest:
ASCO President Dr. Lynn Schuchter on Her Top News From the 2024 MeetingLynn Schuchter, MD, 2023-2024 ASCO president, discusses her top abstracts from the annual meeting.
Latest:
Next Generation Novel Agents for Aggressive B-Cell LymphomaA SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.
Latest:
Trastuzumab Deruxtecan Shows Promising Efficacy for HER2-Mutated NSCLCLyudmila Bazhenova, MD, discusses targeted therapies for patients with HER2-mutated non–small cell lung cancer.
Latest:
Dr. Maciej Michal Mrugala on the Efficacy and Further Uses of Temozolomide in GliomasMaciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington
Latest:
Evaluating Systemic Therapies Available for Frontline Treatment of HCCMadappa Kundranda, MD, PhD, discusses the frontline therapeutic options for patients with newly diagnosed hepatocellular carcinoma who are not candidates for surgery or transplant.
Latest:
CAR T Cells and Bispecifics Generate Excitement in Multiple MyelomaMadhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.
Latest:
Clinical Trials Investigating PARP Inhibitors in Prostate CancerMaha H. Hussain, MB, ChB, professor of medicine and deputy director at Robert H. Lurie Comprehensive Cancer Center, discusses the current role of PARP inhibitors in clinical trials for treatment of patients with prostate cancer.
Latest:
PARP Inhibitors Excite Prostate Cancer Treatment ParadigmMaha Hussain, MD, discusses the current role of PARP inhibitors in the treatment landscape of prostate cancers and where she sees this therapeutic approach evolving in the coming years.
Latest:
The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community OncologyThe goal of precision medicine is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.
Latest:
Dr. Mahmoud Al-Hawary on NCCN Imaging Guidelines and Their Role in Pancreatic CancerMahmoud Al-Hawary, MD, discusses the current NCCN guidelines for imaging and how they play a role in patients with pancreatic cancer.
Latest:
Genomic Analysis of CALGB 40601 for HER2-Positive Breast CancerMaki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger Comprehensive Cancer Center, discusses an integrated analysis of multidimensional genomic data on the phase III CALGB 40601 (Alliance) study, which explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib for patients with HER2-positive breast cancer,
Latest:
Dr. Mason Discusses the PROTECT Study in Localized Prostate CancerMalcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> ​
Latest:
Analyzing the DESTINY-Gastric01 Trial for Gastric or GEJ AdenocarcinomaManish A. Shah, MD, discusses the design and efficacy of the DESTINY-Gastric01 trial of trastuzumab deruxtecan in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Latest:
Results for Phase III GAMMA-1 Trial in Patients With Advanced Gastric CancersManish A. Shah, MD, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Latest:
Novel Targets in Gastric CancerManish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell discusses novel targets in gastric cancer outside of HER2.
Latest:
The Utility of Pomalidomide in R/R Multiple MyelomaManish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.
Latest:
Niraparib Shows Positive Data, Requires Different Dosing in Ovarian CancerMansoor R. Mirza, MD, discusses the results of the PRIMA study of niraparib in patients with advanced ovarian cancer and the evaluation of the starting dose in these patients.
Latest:
Phase II Trial of Elderly Patients With Newly Diagnosed Multiple MyelomaMarÃa-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.
Latest:
Treatment of Smoldering Myeloma Delays Disease Progression, Yet Questions RemainThere are many greatdebates in the field of multiple myeloma, and one that is becoming increasingly relevant in the era of modern therapies is whether or not to treat patients with asymptomatic disease. While the etiology of MM remains unknown, a major advancement in understanding myeloma pathogenesis has been the observation that all patientsprogress, albeit at differing rates, through an asymptomatic phase of either monoclonal gammopathy of undetermined significance or smoldering MM.
Latest:
Strategies for Managing Patients With MelanomaMarc S. Ernstoff, MD, provides recommendations for managing patients with metastatic melanoma.
Latest:
Therapies Discussed at CFS Show Responses for Hematologic MalignanciesMarc J. Braunstein, MD, PhD, discusses chimeric antigen receptor T-cell therapies, Bruton’s kinase inhibitors, and brentuximab vedotin that were highlighted at the 2020 Chemotherapy Foundation Symposium.
Latest:
Looking Ahead: The Treatment of Colorectal CancerMarc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, comments on the future of the treatment of patients with colorectal cancer.
Latest:
CAR T Cell Therapies for ALL and NHLMarcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
Latest:
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCLMarcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Latest:
Unpacking the Future of Thyroid Cancer TreatmentMarcia S. Brose, MD, PhD, FASCO, discusses potential next steps for approaching and treating patients with advanced or metastatic RET-mutant thyroid cancer.
Latest:
The Significant Need for New Agents to Treat MDSMarco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the significant need for new agents to treat MDS.
